Kaposi Sarcoma in case of solid organ transplantation

Kaposi sarcoma (KS) is a soft tissue cancer that is related to several intrinsic and environ­mental factors. In the general population, KS is an extremely rare tumor, however, the risk of its development is substantially increased in immune compromised patients including patients with acquired immune deficiency syndrome (AIDS) and solid organ recipients. Genetic predisposition, seropositivity for human herpes virus type HHV, and increased HHV prevalence in the general population are some proposed factors for the development of KS. Middle East is reported as a highly prevalent region for the incidence of post-transplant KS, reports from Saudi Arabia, Egypt and Turkey indicate a high incidence of this disease. Kaposi sarcoma was first described by Moritz Kaposi in the 1870, the disease was a medical curiosity in Europe and the United States until the acquired immunodeficiency syndrome was recognized in 1981.

 

    Related Conference of Kaposi Sarcoma in case of solid organ transplantation

    July 08-08, 2022

    9th World Congress on Human Genetics and Genetic Diseases

    Singapore City, Singapore
    July 11-12, 2022

    26th Global Congress on Biotechnology

    Vienna, Austria
    August 25-25, 2022

    7th International Conference on Molecular Medicine and Diagnostics

    Singapore City, Singapore
    September 19-20, 2022

    International Summit on Genomics and Proteomics

    Dublin, Ireland
    September 19-20, 2022

    15th World Congress on Stem Cell Research

    Dublin, Ireland
    October 17-18, 2022

    21st International Conference on Structural Biology

    Barcelona, Spain
    November 21-22, 2022

    4th Annual summit on Cell Signaling and Cancer Therapy

    Montreal, Canada

    Kaposi Sarcoma in case of solid organ transplantation Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in